Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder Part 1 Epidemiology, Pharmacology, and Impact on Hemodynamics and Ventricular RepolarizationFay, Thomas B., MD*; Alpert, Martin A., MD†Cardiology in Review: May/June 2019 - Volume 27 - Issue 3 - p 113–121 doi: 10.1097/CRD.0000000000000233 Review Articles Buy Abstract Author InformationAuthors Article MetricsMetrics Attention-deficit/hyperactivity disorder (ADHD) is a clinical syndrome characterized by persistent inattention, impulsivity, and hyperactivity. It is most commonly encountered in children and adolescents but may persist into adulthood. A variety of psychostimulant and nonpsychostimulant medications have proven to be successful in reducing inattention, impulsivity, and hyperactivity in those with ADHD. Psychostimulants used to treat ADHD include methylphenidate and related drugs and various amphetamine preparations. Non-psychostimulant medications used to treat ADHD include atomoxetine and two alpha-2 adrenergic agonists: guanfacine extended-release and clonidine extended-release. The psychostimulants and atomoxetine have been shown, on average, to increase heart rate by 3–10 beats/min, systolic blood pressure by 3–8 mm Hg, and diastolic blood pressure by 2–14 mm Hg. These drugs may also delay ventricular repolarization. The alpha-2 adrenergic agonists may reduce heart rate and blood pressure. For these reasons, there is concern about the safety of psychostimulant and nonpsychostimulant medications in patients with ADHD. In part 1 of this review, we discuss the epidemiology and natural history of ADHD, describe the pharmacology of drugs used to treat ADHD, and discuss in detail studies assessing the effects of ADHD drugs on blood pressure, heart or pulse rate, and electrocardiographic indices of ventricular repolarization. From the *Department of Pathology, St. Louis University School of Medicine, St. Louis, MO †Division of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO. Disclosure: The authors have no conflicts of interest to report. Correspondence: Martin A. Alpert, MD, University of Missouri, Health Sciences Center, Room CE 338, One Hospital Drive, Columbia, MO 65212. E-mail: firstname.lastname@example.org. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.